Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Coya Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for Coya Therapeutics, Inc.

COYA

Coya Therapeutics, Inc.

About Coya Therapeutics, Inc.

Coya Therapeutics is a clinical-stage biotech focused on developing therapies that enhance regulatory T cell (Treg) function to treat neurodegenerative, autoimmune, and metabolic diseases. Its core products include biologics, Treg-derived exosomes, and autologous Treg cell therapies, targeting immune dysregulation. The company leverages innovative combination approaches, aiming to restore immune balance and address high unmet medical needs in complex inflammatory conditions.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Coya Therapeutics, Inc.

1
1
Coya Therapeutics, Inc. Coya Therapeutics Reports Q1 2026 Financial Results with $7.2 Million Net Loss

Via official filing (AI summary) | 23 days ago | 0 comments

2
1
Coya Therapeutics, Inc. Coya Therapeutics Reports $21.2 Million Net Loss and Increased Collaboration Revenue in 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Coya Therapeutics, Inc. Coya Therapeutics Reports $3.6 Million Collaboration Revenue in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Coya Therapeutics, Inc. Coya Therapeutics Reports 95% Decline in Collaboration Revenue and Increased Net Loss for Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Coya Therapeutics, Inc. Coya Therapeutics Reports 9-Month Financial Results, Collaboration Revenue Growth, and Strategic Advancements in Clinical Programs

Via official filing (AI summary) | over 1 year ago | 0 comments